Immune network theory

The immune network theory is a theory of how the adaptive immune system works, that has been developed since 1974 mainly by Niels Jerne[1] and Geoffrey W. Hoffmann.[2][3] The theory states that the immune system is an interacting network of lymphocytes and molecules that have variable (V) regions. These V regions bind not only to things that are foreign to the vertebrate, but also to other V regions within the system. The immune system is therefore seen as a network, with the components connected to each other by V-V interactions.

It has been suggested that the phenomena that the theory describes in terms of networks are also explained by clonal selection theory.[4][5] The scope of the symmetrical network theory developed by Hoffmann includes the phenomena of low dose and high dose tolerance, first reported for a single antigen by Avrion Mitchison,[6] and confirmed by Geoffrey Shellam and Sir Gustav Nossal,[7] the helper[8] and suppressor roles[9] of T cells, the role of non-specific accessory cells in immune responses,[10] and the very important phenomenon called I-J. Jerne was awarded the Nobel Prize for Medicine or Physiology in 1984 partly for his work towards the clonal selection theory, as well as his proposal of the immune network concept.[11]

Immune network theory has also inspired a subfield of optimization algorithms similar to artificial neural networks, and unrelated to biological immunology.[12]

The symmetrical immune network theory

Heinz Kohler was involved in early idiotypic network research and was the first to suggest that idiotypic network interactions are symmetrical.[13] Geoffrey W. Hoffmann[2][3] developed a detailed immune network theory based on symmetrical stimulatory, inhibitory and killing interactions. It offers a framework for understanding a large number of immunological phenomena based on a small number of postulates. The theory involves roles for B cells that make antibodies, T cells that regulate the production of antibodies by B cells, and non-specific accessory cells (A cells).

Antibodies called IgG have two V regions and a molecular weight of 150,000. A central role in the theory is played by specific T cell factors, which have a molecular weight of approximately 50,000, and are postulated in the theory to have only one V region.[9][10][14] Hoffmann has proposed that for brevity specific T cell factors should be called tabs.[3] Tabs are able to exert a powerful suppressive effect on the production of IgG antibodies in response to foreign substances (antigens), as has been demonstrated rigorously by Tomio Tada and his collaborators.[9] In the symmetrical network theory tabs are able to block V regions and also to have a stimulatory role when bound to a tab receptor on A cells. Symmetrical stimulatory interactions follow from the postulate that activation of B cells, T cells and A cells involves cross-linking of receptors.

The symmetrical network theory has been developed with the assistance of mathematical modeling. In order to exhibit immune memory to any combination of a large number of different pathogens, the system has a large number of stable steady states. The system is also able to switch between steady states as has been observed experimentally. For example, low or high doses of an antigen can cause the system to switch to a suppressed state for the antigen, while intermediate doses can cause the induction of immunity.

Resolution of the I-J paradox

The theory accounts for the ability of T cells to have regulatory roles in both helping and suppressing immune responses. In 1976 two groups independently reported a phenomenon in mice called I-J.[15][16] From the perspective of the symmetrical network theory, I-J is one of the most important phenomena in immunology, while for many immunologists who are not familiar with the details of the theory, I-J “does not exist”. This is because I-J seemed to map to within the Major Histocompatibility Complex, and no gene could be found at the site where I-J had been mapped in numerous experiments.[17] This became known as the “I-J paradox”. This paradox resulted in suppressor T cells and tabs, which both express I-J determinants, falling out of favour, together with the symmetrical network theory, that is based on the existence of tabs. In the meantime however, it has been shown that the I-J paradox can be resolved in the context of the symmetrical network theory.[3][18]

The resolution of the I-J paradox involves a process of mutual selection (or “co-selection”) of suppressor T cells and helper T cells, meaning that (a) those suppressor T cells are selected that have V regions with complementarity to as many helper T cells as possible, and (b) helper T cells are selected not only on the basis of their V regions having some affinity for MHC class II, but also on the basis of the V regions having some affinity for the selected suppressor T cell V regions. The helper T cells and suppressor T cells that are co-selected are then a mutually stabilizing construct, and for a given mouse genome, more than one such mutually stabilizing set can exist. This resolution of the I-J paradox leads to some testable predictions.[3]

Relevance for understanding HIV pathogenesis

An immune network model for HIV pathogenesis was published in 1994 [18] postulating that HIV-specific T cells are preferentially infected. The publication of this paper was followed in 2002 with the publication of a paper entitled "HIV preferentially infects HIV specific CD4+ T cells." [19]

Under the immune network theory, the main cause for progression to AIDS after HIV infection is not the direct killing of infected T helper cells by the virus. Following an infection with HIV that manages to establish itself, there is a complex interaction between the HIV virus, the T helper cells that it infects, and T suppressor cells.[20] These three quasispecies apply selective pressure on one another and co-evolve in such a way that the viral epitopes eventually come to mimick the V regions of the main population of T suppressor cells. Once this happens, anti-HIV antibodies can bind to and kill most of the host's T suppressor cell population. This results in the dysregulation of the immune system, and eventually to other further anti-self reactions, including against the T helper cell population. At that point, the adaptive immune system is completely compromised and AIDS ensues. Hence in this model, the onset of AIDS is primarily an auto-immune reaction triggered by the cross-reaction of anti-HIV antibodies with T suppressor cells. Once this induced auto-immunity sets in, removing the HIV virus itself (for instance via HAART) would not be sufficient to restore proper immune function. The co-evolution of the quasispecies mentioned above will take a variable time depending on the initial conditions at the time of infection (i.e. the epitopes of the first infection and the steady state of the host's immune cell population), which would explain why there is a variable period, which differs greatly between individual patients, between HIV infection and the onset of AIDS. It also suggests that conventional vaccines are unlikely to be successful, since they would not prevent the auto-immune reaction. In fact such vaccines may do more harm in certain cases, since if the original infection comes from a source with a "mature" infection, those virions will have a high affinity for anti-HIV T helper cells (see above), and so increasing the anti-HIV population via vaccination only serves to provide the virus with more easy targets.

HIV vaccine based on immune network theory

An HIV vaccine based on immune network theory has been described.[21] The vaccine is modeled on a network theory resolution of the Oudin-Cazenave paradox.[22] This is a phenomenon that makes no sense in the context of clonal selection, without taking idiotypic network interactions into account. The vaccine comprises complexes of an anti-anti-HIV antibody and an HIV antigen, and is designed to induce the production of broadly neutralizing anti-HIV antibodies. A suitable anti-anti-HIV antibody for use in this vaccine is the monoclonal antibody 1F7, which was discovered by Sybille Muller and Heinz Kohler and their colleagues.[23] This monoclonal antibody binds to all of six well characterized broadly neutralizing anti-HIV antibodies.[24]

References

  1. ↑ N. K. Jerne (1974) Towards a network theory of the immune system. Ann. Immunol. (Inst. Pasteur), 125C, 373-389
  2. ↑ 2.0 2.1 Hoffmann G. W. (1975). "A network theory of the immune system". Eur. J. Immunol 5 (638–647): 1975. doi:10.1002/eji.1830050912.
  3. ↑ 3.0 3.1 3.2 3.3 3.4 G. W. Hoffmann (2008) Immune Network Theory. Monograph published at www.physics.ubc.ca/~hoffmann/ni.html
  4. ↑ Varela FJ, Coutinho A (May 1991). "Second generation immune networks". Immunol. Today 12 (5): 159–66. doi:10.1016/S0167-5699(05)80046-5. PMID 1878127.
  5. ↑ Coutinho A (July 1995). "The network theory: 21 years later". Scand. J. Immunol. 42 (1): 3–8. doi:10.1111/j.1365-3083.1995.tb03619.x. PMID 7631141.
  6. ↑ N. A. Mitchison (1964) Induction of immunological paralysis in two zones of dosage. Proc. Royal Soc. London B161, 275-292
  7. ↑ Shellam G. R., Nossal G. J. V. (1968). "The mechanism of induction of immunological paralysis. IV. The effects of ultra-low doses of flagellin". Immunology 14 (2): 273–284. PMC 1409291. PMID 5640947.
  8. ↑ Claman Chaperon, Triplett R. F. (1966). "Immunocompetence of transferred thymus-marrow cell combinations". J. Immunol 97: 928–832.
  9. ↑ 9.0 9.1 9.2 Tada T., Takemori T. (1974). "Selective roles of thymus-derived lymphocytes in the antibody response. I. Differential suppressive effect of carrier-primed T cells on hapten-specific IgM and IgG antibody responses". J. Exp. Med 140 (1): 239–252. doi:10.1084/jem.140.1.239. PMC 2139696. PMID 4134784.
  10. ↑ 10.0 10.1 Evans R., Grant C. K., Cox H., Steel K., Alexander P. (1972). "Thymus-derived lymphocytes produce an immunologically specific macrophage-arming factor". J. Exp. Med 136 (5): 1318–1322. doi:10.1084/jem.136.5.1318. PMC 2139296. PMID 4117192.
  11. ↑ The Nobel Prize in Physiology or Medicine 1984
  12. ↑ e.g. Campelo F, Guimarães FG, Igarashi H, Ramírez JA, Noguchi S (2006). "A Modified Immune Network Algorithm for Multimodal Electromagnetic Problems". IEEE Trans. Magnetics 42 (4): 1111–1114. doi:10.1109/TMAG.2006.871633. ISSN 0018-9464.
  13. ↑ Kohler, H. (1975) Transplant. Rev., 27, 24
  14. ↑ Nelson D. S. (1970). "Studies on cytophilic antibodies. A mouse serum "antibody" having an affinity for macrophages and fast alpha-globulin mobility. Austral. J. Exp. Biol. Med". Sci 48: 329–341.
  15. ↑ Murphy D. B., Herzenberg L. A., Herzenberg L. A., Okumura K., McDevitt H. O. (1976). "A new I sub-region (I-J) marked by a locus (Ia-4) controlling surface determinants on suppressor T lymphocytes". J. Exp. Med 144 (3): 699–712. doi:10.1084/jem.144.3.699. PMC 2190409. PMID 1085338.
  16. ↑ Tada T., Taniguchi M., David C. S. (1976). "Properties of the antigen-specific suppressive T-cell factor in the regulation of antibody response of the mouse. IV. Special subregion assignment of the gene that codes for the suppressive T-cell factor in the H-2 histocompatibility complex". J. Exp. Med 144 (3): 713–725. doi:10.1084/jem.144.3.713. PMC 2190403. PMID 1085339.
  17. ↑ Steinmetz M.; Minard K.; Horvath S.; McNicholas J.; Srelinger J.; Wake C.; Long E.; Mach B.; Hood L. (1982). "A molecular map of the immune response region from the histocompatibility complex of the mouse". Nature 300 (5887): 35–42. doi:10.1038/300035a0. PMID 6290895.
  18. ↑ 18.0 18.1 G. W. Hoffmann (1994) Co-selection in immune network theory and in AIDS pathogenesis. Immunology and Cell Biology, 72, 338-346
  19. ↑ Douek D. C., J. M. Brenchley, M. R. Betts, D. R. Ambrozak, B. J. Hill, Y. Okamoto, J. P. Casazza, J. Kuruppu, K. Kunstman, S. Wolinsky, Z. Grossman, M. Dybul, A. Oxenius, D. A. Price, M. Connors and R. A. Koup. (2002) Nature 417, 95-98
  20. ↑ G. W. Hoffmann, Immune Network Theory, Chapter 16
  21. ↑ G. W. Hoffmann, S. Muller, H. Kohler (2012) Towards an HIV vaccine based on immune network theory. Current Trends in Immunology 13, 69-79.
  22. ↑ J. Oudin, P-A. Cazenave (1971) Proc. Natl. Acad. Sci. USA 68, 2616-2620.
  23. ↑ Wang, H., Muller, S., Zolla-Pazna, S., and Kohler, H. (1992) Eur. J. Immunol., 22, 1749.
  24. ↑ Parsons M. S., Rouleau, D., Routy, J-P., LeBlanc, R., Grant, M. D., and Bernard, N. F. (2011) AIDS, 25, 1259.

Further reading